Drug
Cch Aaes
Cch Aaes: highest development phase Post-Market, developed by Endo. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Endo
Trials
| Drug | Phase | Indication |
|---|---|---|
| CCH-aaes NCT04677712 | Post-Market | Edematous Fibrosclerotic Panniculopathy (EFP) |
Latest
No recent events.
Follow Cch Aaes on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.